Drug Trial Radar · NCT00595413
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
Last checked: Nov 20, 2026Latest source record: Feb 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
311
Actual
Start
Sep 2007
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- EMD SeronoIndustry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Jan 16, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of atacicept compared to placebo in the treatment of signs and symptoms in a subject population with active rheumatoid arthritis (RA), inadequate response to methotrexate (MTX) and no previous exposure to anti-tumor necrosis factor alpha (anti-TNFalpha) therapy.
Conditions
- Rheumatoid Arthritis
Interventions
Placebo matched to ataciceptDrug
Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
Atacicept: with loading doseDrug
Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
AtaciceptDrug
Atacicept will be administered subcutaneously at a dose of 150 mg once a week for 25 weeks.
AdalimumabBiological
Adalimumab (Humira®) will be administered subcutaneously at a dose of 40 mg every other week for 25 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26Time frame: Week 26
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Please Contact US Medical Information
Rockland, Massachusetts
Please contact the Merck KGaA Communication Center
Darmstadt, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.